82
Participants
Start Date
May 18, 2016
Primary Completion Date
October 8, 2016
Study Completion Date
April 18, 2017
Nicotine Metabolite Ratio
This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.
Varenicline
FDA-approved smoking cessation pharmacotherapy
Bupropion
FDA-approved smoking cessation pharmacotherapy
Nicotine patch
FDA-approved smoking cessation pharmacotherapy
Vanderbilt University Medical Center
OTHER